Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CCL2 | P13500 | 1/20 | 0.35 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18650893 | 1.00 | F10 (0.37) | F10PTGS2BRD4CCL2BAZ2A | |
| SCHEMBL18668089 | 0.90 | F10 (0.36) | F10PTGS2BRD4CCL2BAZ2A | |
| SCHEMBL18650895 | 0.90 | BACE1 (0.37) | F10PTGS2BRD4CCL2BAZ2A | |
| SCHEMBL18650907 | 0.85 | LRRK2 (0.33) | F10PTGS2LRRK2 | |
| SCHEMBL18631316 | 0.83 | BACE1 (0.38) | F10PTGS2BRD4CCL2BAZ2A | |
| SCHEMBL18650896 | 0.83 | TLR8 (0.39) | F10PTGS2BRD4LRRK2GPR119 | |
| SCHEMBL18650884 | 0.79 | PTGS2 (0.33) | F10PTGS2LRRK2GPR119KLKB1 | |
| SCHEMBL18650897 | 0.78 | BRD4 (0.34) | F10PTGS2BRD4LRRK2GPR119 | |
| SCHEMBL18650885 | 0.77 | BACE1 (0.34) | F10PTGS2LRRK2GPR119KLKB1 | |
| SCHEMBL18650892 | 0.77 | LRRK2 (0.35) | F10PTGS2LRRK2GPR119KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | F10 4686/4885PTGS2 3203/4885BRD4 176/4885 |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | F10 4686/4885PTGS2 3203/4885BRD4 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.